Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEF ADVANCED RESEARCH PROJECTS AGCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

DARPA-PS-26-124

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AC12

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
The Defense Advanced Research Projects Agency (DARPA), operating under the Department of Defense, has issued a solicitation (DARPA-PS-26-124) for the Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program, specifically seeking proposals for Phase 1 of Task Area 1 (TA-1) and/or Task Area 2 (TA-2). This initiative is classified under NAICS code 541714, which pertains to Research and Development in Biotechnology (except Nanobiotechnology), and is further identified by Product Service Code AC12. The RAPIID program is a forward-looking effort aimed at revolutionizing trauma care in austere and far-forward environments. Its primary objective is to develop a comprehensive, deployable resuscitation system that can match or surpass the efficacy of stored whole blood for early resuscitation, while eliminating reliance on cold chain logistics and donor blood supplies. The envisioned solution centers on a blood analog system (BAS), which will consist of sequentially administered blood analog components. These components are to be integrated with ruggedized delivery formats, point-of-care diagnostic tools, and clinical practice guidelines (CPGs), ensuring the system is practical, scalable, and suitable for field deployment. A critical aspect of the RAPIID program is its focus on the full lifecycle of product development, including regulatory and commercialization strategies to ensure post-program viability. The program aims to advance blood analog components to Technology Readiness Level (TRL) 7, encompassing scale-up and Phase II clinical trials, and to bring associated devices and diagnostics to TRL 8, which includes clinical studies. This solicitation is limited to Phase 1 activities within TA-1 and/or TA-2, and does not encompass the entire scope of the RAPIID program. Offerors are expected to address the initial development and demonstration of their proposed solutions within these task areas. The solicitation also includes recent updates clarifying program coordination across task areas, acquisition strategy, and the removal of broken links in the documentation. The contracting entity for this opportunity is the Defense Advanced Research Projects Agency (DARPA), with the BAA Coordinator serving as the primary point of contact. Interested parties may direct inquiries to [email protected]. The solicitation was posted on May 28, 2026, and responses are due by June 24, 2026. This opportunity is particularly relevant for organizations with expertise in biotechnology research and development, especially those capable of advancing innovative trauma care solutions through early-stage development and regulatory planning. Contractors should carefully review the solicitation documents and attachments available via the official SAM.gov listing (https://sam.gov/opp/13dca662b7da444593550da9d021d533/view) to ensure alignment with their technical capabilities and strategic interests. No set-aside requirements or special considerations are specified in the provided information.
Documents9